Lyell Immunopharma, Inc. Operating Cash Flow
Lyell Immunopharma, Inc. (LYEL) reported Operating Cash Flow of -$72.43 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- Lyell Immunopharma, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$33.92M.
- Lyell Immunopharma, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$38.51M.
- Lyell Immunopharma, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$32.25M.
- Lyell Immunopharma, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$28.58M.
- Lyell Immunopharma, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$150.02M.
- Lyell Immunopharma, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$162.39M.
- Lyell Immunopharma, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$163.69M.
- Lyell Immunopharma, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$169.56M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$33.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$72.43M 10-Q · filed 2026-08-06 | -$104.68M derived: sum of 3 quarters · filed 2026-08-06 | -$133.26M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | -$38.51M 10-Q · filed 2026-05-06 | -$70.76M derived: sum of 2 quarters · filed 2026-05-06 | -$99.34M derived: sum of 3 quarters · filed 2026-05-06 | -$133.80M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | -$32.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$60.83M derived: sum of 2 quarters · filed 2026-03-12 | -$95.29M derived: sum of 3 quarters · filed 2026-08-06 | -$150.02M 10-K · filed 2026-03-12 | |
| 2025-09-30 | -$28.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$63.03M derived: sum of 2 quarters · filed 2026-08-06 | -$117.77M 10-Q · filed 2025-11-12 | -$165.01M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | -$34.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$89.20M 10-Q · filed 2026-08-06 | -$136.44M derived: sum of 3 quarters · filed 2026-08-06 | -$171.48M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | -$54.74M 10-Q · filed 2026-05-06 | -$101.98M derived: sum of 2 quarters · filed 2026-05-06 | -$137.02M derived: sum of 3 quarters · filed 2026-05-06 | -$175.12M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | -$47.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$82.28M derived: sum of 2 quarters · filed 2026-03-12 | -$120.38M derived: sum of 3 quarters · filed 2026-03-12 | -$162.39M 10-K · filed 2026-03-12 | |
| 2024-09-30 | -$35.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$73.14M derived: sum of 2 quarters · filed 2025-11-12 | -$115.15M 10-Q · filed 2025-11-12 | -$155.79M derived: sum of 4 quarters · filed 2026-03-12 | |
| 2024-06-30 | -$38.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$80.11M 10-Q · filed 2025-08-12 | -$120.75M derived: sum of 3 quarters · filed 2026-03-12 | -$158.43M derived: sum of 4 quarters · filed 2026-03-12 | |
| 2024-03-31 | -$42.02M 10-Q · filed 2025-05-13 | -$82.65M derived: sum of 2 quarters · filed 2026-03-12 | -$120.34M derived: sum of 3 quarters · filed 2026-03-12 | -$159.50M derived: sum of 4 quarters · filed 2026-03-12 | |
| 2023-12-31 | -$40.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$78.32M derived: sum of 2 quarters · filed 2026-03-12 | -$117.48M derived: sum of 3 quarters · filed 2026-03-12 | -$163.69M 10-K · filed 2026-03-12 | |
| 2023-09-30 | -$37.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$76.85M derived: sum of 2 quarters · filed 2024-11-07 | -$123.06M 10-Q · filed 2024-11-07 | -$163.33M derived: sum of 4 quarters · filed 2025-03-11 | |
| 2023-06-30 | -$39.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$85.37M 10-Q · filed 2024-08-07 | -$125.64M derived: sum of 3 quarters · filed 2025-03-11 | -$162.74M derived: sum of 4 quarters · filed 2025-03-11 | |
| 2023-03-31 | -$46.21M 10-Q · filed 2024-05-06 | -$86.48M derived: sum of 2 quarters · filed 2025-03-11 | -$123.58M derived: sum of 3 quarters · filed 2025-03-11 | -$167.91M derived: sum of 4 quarters · filed 2025-03-11 | |
| 2022-12-31 | -$40.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$77.37M derived: sum of 2 quarters · filed 2025-03-11 | -$121.70M derived: sum of 3 quarters · filed 2025-03-11 | -$169.56M 10-K · filed 2025-03-11 | |
| 2022-09-30 | -$37.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$81.44M derived: sum of 2 quarters · filed 2023-11-07 | -$129.29M 10-Q · filed 2023-11-07 | -$162.50M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2022-06-30 | -$44.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$92.19M 10-Q · filed 2023-08-08 | -$125.40M derived: sum of 3 quarters · filed 2024-02-28 | -$150.89M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2022-03-31 | -$47.85M 10-Q · filed 2023-05-04 | -$81.06M derived: sum of 2 quarters · filed 2024-02-28 | -$106.56M derived: sum of 3 quarters · filed 2024-02-28 | -$140.50M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2021-12-31 | -$33.21M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$58.70M derived: sum of 2 quarters · filed 2024-02-28 | -$92.65M derived: sum of 3 quarters · filed 2024-02-28 | -$126.25M 10-K · filed 2024-02-28 | |
| 2021-09-30 | -$25.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$59.44M derived: sum of 2 quarters · filed 2022-11-08 | -$93.04M 10-Q · filed 2022-11-08 | -$93.08M 10-Q · filed 2021-11-12 | -$119.77M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$33.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$67.54M 10-Q · filed 2022-08-04 | -$94.28M derived: sum of 3 quarters · filed 2023-02-28 | -$115.90M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-03-31 | -$33.60M 10-Q · filed 2022-05-10 | -$60.33M derived: sum of 2 quarters · filed 2023-02-28 | -$81.96M derived: sum of 3 quarters · filed 2023-02-28 | ||
| 2020-12-31 | -$26.73M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$48.36M derived: sum of 2 quarters · filed 2023-02-28 | -$160.87M 10-K · filed 2023-02-28 | ||
| 2020-09-30 | -$21.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$134.14M 10-Q · filed 2021-11-12 | |||
| 2020-06-30 | -$112.51M 10-Q · filed 2021-08-12 | ||||
| 2019-12-31 | $39.47M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |